SG11201405764YA - Compounds and methods for kinase modulation, and indications therefor - Google Patents
Compounds and methods for kinase modulation, and indications thereforInfo
- Publication number
- SG11201405764YA SG11201405764YA SG11201405764YA SG11201405764YA SG11201405764YA SG 11201405764Y A SG11201405764Y A SG 11201405764YA SG 11201405764Y A SG11201405764Y A SG 11201405764YA SG 11201405764Y A SG11201405764Y A SG 11201405764YA SG 11201405764Y A SG11201405764Y A SG 11201405764YA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- methods
- kinase modulation
- indications therefor
- indications
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612912P | 2012-03-19 | 2012-03-19 | |
| US201361754318P | 2013-01-18 | 2013-01-18 | |
| US13/802,106 US9358235B2 (en) | 2012-03-19 | 2013-03-13 | Kinase modulation, and indications therefor |
| PCT/US2013/032835 WO2013142427A1 (en) | 2012-03-19 | 2013-03-18 | Compounds and methods for kinase modulation, and indications therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405764YA true SG11201405764YA (en) | 2014-10-30 |
Family
ID=48045777
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607813SA SG10201607813SA (en) | 2012-03-19 | 2013-03-18 | Compounds and methods for kinase modulation, and indications therefor |
| SG11201405764YA SG11201405764YA (en) | 2012-03-19 | 2013-03-18 | Compounds and methods for kinase modulation, and indications therefor |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607813SA SG10201607813SA (en) | 2012-03-19 | 2013-03-18 | Compounds and methods for kinase modulation, and indications therefor |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9358235B2 (en) |
| EP (2) | EP2827904A1 (en) |
| JP (1) | JP6165837B2 (en) |
| KR (2) | KR102350088B1 (en) |
| CN (1) | CN104703623B (en) |
| AU (2) | AU2013235298A1 (en) |
| BR (1) | BR112014023162A8 (en) |
| CA (1) | CA2867918C (en) |
| EA (1) | EA029676B1 (en) |
| HK (1) | HK1204995A1 (en) |
| IL (1) | IL234702A (en) |
| MY (1) | MY176903A (en) |
| NZ (1) | NZ630483A (en) |
| SG (2) | SG10201607813SA (en) |
| WO (1) | WO2013142427A1 (en) |
| ZA (1) | ZA201407580B (en) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| CA2695004C (en) | 2007-07-17 | 2016-01-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| NZ594398A (en) | 2009-04-03 | 2014-03-28 | Plexxikon Inc | Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof |
| US20110112127A1 (en) | 2009-11-06 | 2011-05-12 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA2781287C (en) | 2009-11-18 | 2018-07-31 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN102753549A (en) | 2009-12-23 | 2012-10-24 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
| TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| ES2696023T3 (en) | 2011-02-07 | 2019-01-11 | Plexxikon Inc | Compounds and methods for the modulation of kinases and indications for this |
| WO2012158957A2 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| ES2889757T3 (en) | 2012-09-06 | 2022-01-13 | Plexxikon Inc | Compounds and methods for the modulation of kinases and indications for these |
| CA2895239C (en) | 2012-12-21 | 2020-10-27 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RU2680100C9 (en) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Heterocyclic compounds and uses thereof |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| RU2015149937A (en) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION |
| CN104710417B (en) * | 2013-12-11 | 2020-09-08 | 上海科州药物研发有限公司 | Azaindole derivatives and synthesis method thereof |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2015164862A1 (en) * | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
| WO2016004272A1 (en) | 2014-07-02 | 2016-01-07 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CN105384754B (en) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | Heterocycle compound as kinases inhibitor and its preparation method and application |
| EP3194392B1 (en) | 2014-09-15 | 2020-01-01 | Plexxikon, Inc. | Heterocyclic compounds and uses thereof |
| WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6530826B2 (en) | 2015-05-06 | 2019-06-12 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | Synthesis of 1H-pyrrolo [2,3-B] pyridine derivatives that modify kinases |
| SI3292123T1 (en) | 2015-05-06 | 2020-10-30 | Plexxikon Inc. | Solid forms of a compound modulating kinases |
| HUE050936T2 (en) | 2015-05-22 | 2021-01-28 | Plexxikon Inc | Synthesis of heterocyclic compounds |
| JP2018515570A (en) | 2015-05-22 | 2018-06-14 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | PLX-8394 or PLX-7904 for use in the treatment of BRAF-V600 related diseases |
| WO2016188816A1 (en) * | 2015-05-22 | 2016-12-01 | Ucb Biopharma Sprl | Treatment of epilepsy |
| JP6851322B2 (en) * | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | How to treat neurological disorders |
| IL276292B2 (en) * | 2015-07-20 | 2024-02-01 | Genzyme Corp | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MY195977A (en) | 2015-09-21 | 2023-02-27 | Plexxikon Inc | Heterocyclic Compounds and uses Thereof |
| CN105131013A (en) * | 2015-10-18 | 2015-12-09 | 淄博夸克医药技术有限公司 | Novel macrolide compound and preparation method and medical application thereof |
| WO2017100201A1 (en) | 2015-12-07 | 2017-06-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| KR102445255B1 (en) | 2016-03-02 | 2022-09-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Eribulin-Based Antibody-Drug Conjugates and Methods of Use |
| CA3017972C (en) | 2016-03-16 | 2023-03-28 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| WO2018001270A1 (en) * | 2016-06-30 | 2018-01-04 | Noratech Pharmaceuticals, Inc. | Palbociclib prodrugs and composition thereof |
| TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
| CA3047580A1 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
| JP7300394B2 (en) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death |
| CA3056777A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| JP2020512364A (en) * | 2017-03-28 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Nintedanib for use in a method of treating muscular dystrophy |
| WO2018182527A1 (en) * | 2017-03-30 | 2018-10-04 | National University Of Singapore | Method for treating inflammatory complications in eye diseases |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| TWI805599B (en) | 2017-07-25 | 2023-06-21 | 美商第一三共公司 | Formulations of a compound modulating kinases |
| CN109549940A (en) * | 2017-09-26 | 2019-04-02 | 广西梧州制药（集团）股份有限公司 | A kind of Pyrazolopyrimidine derivative external preparation and preparation method thereof |
| CN109549941A (en) * | 2017-09-26 | 2019-04-02 | 广西梧州制药（集团）股份有限公司 | A kind of purposes of Pyrazolopyrimidine derivative in terms of disease medicament is treated in preparation |
| CN111194318B (en) | 2017-10-13 | 2023-06-09 | Opna生物公司 | Solid forms of compounds for modulating kinases |
| EP3700574A1 (en) | 2017-10-27 | 2020-09-02 | Plexxikon Inc. | Formulations of a compound modulating kinases |
| CN112119072A (en) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | Compounds and methods for IDO and TDO modulation, and indications thereof |
| EP3950063A4 (en) * | 2019-03-29 | 2022-11-30 | Kowa Company, Ltd. | Novel azaindole derivative |
| US11446287B2 (en) | 2019-04-09 | 2022-09-20 | Opna Immuno-Oncology Sa | Compounds and methods for EP300 or CBP modulation and indications therefor |
| US20220213064A1 (en) * | 2019-04-12 | 2022-07-07 | National Health Research Institutes | Heterocyclic compounds as kinase inhibitors for therapeutic uses |
| JP2023506768A (en) | 2019-12-12 | 2023-02-20 | ティン セラピューティックス エルエルシー | Compositions and methods for prevention and treatment of hearing loss |
| TW202206422A (en) | 2020-04-23 | 2022-02-16 | 美商普雷辛肯公司 | Compounds and methods for cd73 modulation and indications therefor |
| CA3185968A1 (en) | 2020-07-13 | 2022-01-20 | Tony Lahoutte | Antibody fragment against folr1 |
| JP2023542473A (en) | 2020-08-21 | 2023-10-10 | プレキシコン インコーポレーテッド | Combination drug anticancer treatment |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| KR20220133109A (en) | 2021-03-24 | 2022-10-04 | 재단법인 아산사회복지재단 | Composition for Differential Diagnosis of Malignant Peripheral Nerve Sheath Tumor |
| WO2023179793A1 (en) * | 2022-03-25 | 2023-09-28 | 成都嘉葆药银医药科技有限公司 | Crystal form of 1h-pyrrolo[2,3-c]pyridine compound and preparation method therefor |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| CN114736204A (en) * | 2022-05-06 | 2022-07-12 | 湖北工业大学 | Preparation method of pexidaltinib structural analogue and application of pexidaltinib structural analogue in tumor resistance |
| CN115054592A (en) * | 2022-07-06 | 2022-09-16 | 复旦大学附属中山医院 | Application of compound in preparation of medicine for treating proliferative hepatocellular carcinoma |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2248784A1 (en) | 1996-06-25 | 1997-12-31 | Takeda Chemical Industries, Ltd. | Oxazolone derivatives and their use |
| US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
| ES2666694T3 (en) | 2002-09-06 | 2018-05-07 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for the delivery of covalently bound therapeutic agents to them |
| WO2004024895A2 (en) | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
| US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| JP2007524374A (en) | 2003-02-28 | 2007-08-30 | プレキシコン，インコーポレーテッド | PYK2 crystal structure and use |
| US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
| US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| NZ545326A (en) | 2003-07-17 | 2009-12-24 | Plexxikon Inc | PPAR active compounds |
| US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| EP1673085B1 (en) * | 2003-09-26 | 2011-11-09 | Exelixis, Inc. | C-met modulators and methods of use |
| JP5138938B2 (en) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Compounds and methods for the development of RET modulators |
| US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
| JP2008503446A (en) | 2004-05-06 | 2008-02-07 | プレキシコン，インコーポレーテッド | PDE4B inhibitor and use thereof |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| CA2570817A1 (en) | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
| NZ553267A (en) | 2004-07-27 | 2010-09-30 | Sgx Pharmaceuticals Inc | Pyrrolo-pyridine kinase modulators |
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| EP1786813A2 (en) | 2004-09-03 | 2007-05-23 | Plexxikon, Inc. | Bicyclic heteroaryl pde4b inhibitors |
| WO2006060535A2 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
| EP1819673A2 (en) | 2004-11-30 | 2007-08-22 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
| US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
| US20060160837A1 (en) * | 2004-12-29 | 2006-07-20 | The Brigham And Women's Hospital, Inc. | Rapamycin compounds in the treatment of neurofibromatosis type 1 |
| EP1885723A2 (en) | 2005-05-17 | 2008-02-13 | Plexxikon, Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| RS52010B (en) | 2005-06-22 | 2012-04-30 | Plexxikon Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
| RU2419618C2 (en) | 2005-09-07 | 2011-05-27 | Плекссикон, Инк. | Compounds, active towards ppar (peroxisome proliferator-activated receptor) |
| JP2009509932A (en) | 2005-09-07 | 2009-03-12 | プレキシコン，インコーポレーテッド | PPAR active compounds |
| TW200800872A (en) | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| MX2009006688A (en) | 2006-12-21 | 2009-06-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20121126A1 (en) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
| PE20090159A1 (en) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | INDOL-PROPIONIC ACID DERIVED COMPOUNDS AS PPARs MODULATORS |
| EP2121591A2 (en) | 2007-03-08 | 2009-11-25 | Plexxikon, Inc. | Ppar active compounds |
| CA2695004C (en) | 2007-07-17 | 2016-01-19 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20091846A1 (en) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS |
| US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AU2009257635A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| WO2010104973A1 (en) | 2009-03-11 | 2010-09-16 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases |
| EP2406259A1 (en) | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| NZ594398A (en) | 2009-04-03 | 2014-03-28 | Plexxikon Inc | Propane-1-sulfonic acid (3-[5-(4-chloro-phenyl)-1h-pyrrol [2, 3-b] pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide compositions and uses thereof |
| MX2011011735A (en) | 2009-05-04 | 2011-11-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor. |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20110112127A1 (en) * | 2009-11-06 | 2011-05-12 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA2781287C (en) | 2009-11-18 | 2018-07-31 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN102753549A (en) | 2009-12-23 | 2012-10-24 | 普莱希科公司 | Compounds and methods for kinase modulation, and indications therefor |
| TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
| ES2696023T3 (en) | 2011-02-07 | 2019-01-11 | Plexxikon Inc | Compounds and methods for the modulation of kinases and indications for this |
| AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
| WO2012158957A2 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
| CN102993199A (en) | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | Heterocycle substituted pyrido-pyrrole kinase inhibitor |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| ES2889757T3 (en) | 2012-09-06 | 2022-01-13 | Plexxikon Inc | Compounds and methods for the modulation of kinases and indications for these |
| CA2895239C (en) | 2012-12-21 | 2020-10-27 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| RU2680100C9 (en) | 2013-03-15 | 2019-04-18 | Плексксикон Инк. | Heterocyclic compounds and uses thereof |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| RU2015149937A (en) | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | COMPOUNDS FOR KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| EP3194392B1 (en) | 2014-09-15 | 2020-01-01 | Plexxikon, Inc. | Heterocyclic compounds and uses thereof |
| WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| SI3292123T1 (en) | 2015-05-06 | 2020-10-30 | Plexxikon Inc. | Solid forms of a compound modulating kinases |
| JP6530826B2 (en) | 2015-05-06 | 2019-06-12 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | Synthesis of 1H-pyrrolo [2,3-B] pyridine derivatives that modify kinases |
| HUE050936T2 (en) | 2015-05-22 | 2021-01-28 | Plexxikon Inc | Synthesis of heterocyclic compounds |
| JP2018515570A (en) | 2015-05-22 | 2018-06-14 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | PLX-8394 or PLX-7904 for use in the treatment of BRAF-V600 related diseases |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MY195977A (en) | 2015-09-21 | 2023-02-27 | Plexxikon Inc | Heterocyclic Compounds and uses Thereof |
| WO2017100201A1 (en) | 2015-12-07 | 2017-06-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CA3017972C (en) | 2016-03-16 | 2023-03-28 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
| TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
-
2013
- 2013-03-13 US US13/802,106 patent/US9358235B2/en active Active
- 2013-03-18 JP JP2015501836A patent/JP6165837B2/en active Active
- 2013-03-18 EA EA201491721A patent/EA029676B1/en not_active IP Right Cessation
- 2013-03-18 AU AU2013235298A patent/AU2013235298A1/en not_active Abandoned
- 2013-03-18 MY MYPI2014702654A patent/MY176903A/en unknown
- 2013-03-18 SG SG10201607813SA patent/SG10201607813SA/en unknown
- 2013-03-18 EP EP13714152.9A patent/EP2827904A1/en not_active Withdrawn
- 2013-03-18 CA CA2867918A patent/CA2867918C/en active Active
- 2013-03-18 KR KR1020207033951A patent/KR102350088B1/en active IP Right Grant
- 2013-03-18 CN CN201380024796.8A patent/CN104703623B/en active Active
- 2013-03-18 SG SG11201405764YA patent/SG11201405764YA/en unknown
- 2013-03-18 EP EP23191645.3A patent/EP4295912A3/en active Pending
- 2013-03-18 WO PCT/US2013/032835 patent/WO2013142427A1/en active Application Filing
- 2013-03-18 KR KR1020147029231A patent/KR20140144229A/en not_active IP Right Cessation
- 2013-03-18 NZ NZ630483A patent/NZ630483A/en unknown
- 2013-03-18 BR BR112014023162A patent/BR112014023162A8/en not_active Application Discontinuation
-
2014
- 2014-09-17 IL IL234702A patent/IL234702A/en active IP Right Grant
- 2014-10-17 ZA ZA2014/07580A patent/ZA201407580B/en unknown
-
2015
- 2015-06-23 HK HK15105961.7A patent/HK1204995A1/en unknown
-
2016
- 2016-05-05 US US15/147,781 patent/US9730918B2/en active Active
-
2017
- 2017-08-04 US US15/669,353 patent/US10123998B2/en active Active
- 2017-10-30 AU AU2017254821A patent/AU2017254821B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201407580B (en) | 2020-05-27 |
| US9358235B2 (en) | 2016-06-07 |
| US9730918B2 (en) | 2017-08-15 |
| HK1204995A1 (en) | 2015-12-11 |
| US20140037617A1 (en) | 2014-02-06 |
| US10123998B2 (en) | 2018-11-13 |
| CN104703623B (en) | 2017-06-23 |
| CN104703623A (en) | 2015-06-10 |
| EP4295912A3 (en) | 2024-03-06 |
| EA201491721A1 (en) | 2015-02-27 |
| KR102350088B1 (en) | 2022-01-12 |
| AU2017254821A1 (en) | 2017-11-16 |
| KR20200139832A (en) | 2020-12-14 |
| US20160243092A1 (en) | 2016-08-25 |
| US20180055828A1 (en) | 2018-03-01 |
| NZ630483A (en) | 2017-08-25 |
| EP2827904A1 (en) | 2015-01-28 |
| MY176903A (en) | 2020-08-26 |
| EP4295912A2 (en) | 2023-12-27 |
| CA2867918C (en) | 2020-05-05 |
| IL234702A (en) | 2017-02-28 |
| BR112014023162A8 (en) | 2018-01-16 |
| WO2013142427A1 (en) | 2013-09-26 |
| AU2017254821B2 (en) | 2019-09-19 |
| JP6165837B2 (en) | 2017-07-19 |
| SG10201607813SA (en) | 2016-11-29 |
| BR112014023162A2 (en) | 2017-06-20 |
| JP2015510944A (en) | 2015-04-13 |
| CA2867918A1 (en) | 2013-09-26 |
| EA029676B1 (en) | 2018-04-30 |
| KR20140144229A (en) | 2014-12-18 |
| AU2013235298A1 (en) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181779T1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| HK1213877A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| HK1204995A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| HK1219732A1 (en) | Compounds for kinase modulation, and indications therefor | |
| EP2892534B8 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| ZA201207898B (en) | Compounds and methods for kinase modulation,and indications therefor | |
| HK1199713A1 (en) | Kinase modulation and indications therefor | |
| EP2906696A4 (en) | Methods for modulating c9orf72 expression | |
| HK1209277A1 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6- | |
| GB201204383D0 (en) | H, level | |
| GB201223020D0 (en) | Tmf | |
| GB201213825D0 (en) | Damper-device for bouncing-device |